July 11, 2020

The Niche

Knoepfler lab stem cell blog

Mike West

2 min read

Stem cell biotech BioTime announced the news today that its subsidiary Cell Cure Neurosciences (Cell Cure) has filed an IND with the FDA for an embryonic stem (ES) cell-based therapy for Dry age-related macular degeneration (AMD). The product to be tested is OpRegen, which the company indicates is “the first IND for an ES cell-based therapy developed in Israel.” Cell Cure in its PR on this IND also listed three other key bullet points: “IND filed for Phase I/IIa dose escalation trial in patients …Read More

3 min read

Who do you turn to when you want to both know the real history of the pluripotent stem cell-based biotech industry and perspectives on its future? There are only a handful of people and one of them is definitely Dr. Michael West, CEO of BioTime. I’m doing a several part series of blog posts on a lengthy phone interview and conversation that I had with West. Today in Part 2 we are focused on clinical development of human ES cells and what happened with …Read More

2 min read

By Jeanne Loring. On Wednesday afternoon at the ISSCR meeting in Boston, Jamie Thomson gave a talk about the history of human pluripotent stem cells. There were probably only a dozen people in the audience of around 3,000 who were working on human ES cells around the same time that Jamie and Joseph Itskovitz-Eldor were collaborating on the first derivation of human ES cells, which was published in 1998.  I found myself laughing (quietly- honest!) at Jamie’s recollections- Mike West approaching him to offer …Read More